Background-Common causative agents in the development of inflammatory cardiomyopathy include cardiotropic viruses such as coxsackievirus B3 (CVB3). Here, we investigated the role of the ubiquitin-like modifier interferon-stimulated gene of 15 kDa (ISG15) in the pathogenesis of viral cardiomyopathy. Methods and Results-In CVB3-infected mice, the absence of protein modification with ISG15 was accompanied by a profound exacerbation of myocarditis and by a significant increase in mortality and heart failure. We found that ISG15 in cardiomyocytes contributed significantly to the suppression of viral replication. In the absence of an intact ISG15 system, virus titers were markedly elevated by postinfection day 8, and viral RNA persisted in ISG15 −/− mice at postinfection day 28. Ablation of the ISG15 protein modification system in CVB3 infection predisposed mice to long-term disease with deposition of collagen fibers, all leading to inflammatory cardiomyopathy. We found that ISG15 acts as part of the intrinsic immunity in cardiomyocytes and detected no significant effects of ISG15 modification on the cellular immune response. ISG15 modification of CVB3 2A protease counterbalanced CVB3-induced cleavage of the host cell eukaryotic initiation factor of translation eIF4G in cardiomyocytes, thereby counterbalancing the shutoff of host cell translation in CVB3 infection. We demonstrate that ISG15 suppressed infectious virus yield in human cardiac myocytes and the induction of ISG15 in patients with viral cardiomyopathy. Conclusions-The ISG15 conjugation system represents a critical innate response mechanism in cardiomyocytes to fight the battle against invading pathogens, limiting inflammatory cardiomyopathy, heart failure, and death. Interference with the ISG15 system might be a novel therapeutic approach in viral cardiomyopathy. response. Type I IFNs contribute to the suppression of viral titers and thereby ameliorate invasion of immune cells into the heart, contributing to improved survival in CVB3 infection. [6] [7] [8] Type I IFN-dependent processes resulted in improved cardiac function during viral cardiomyopathy 7,9 and ensured long-term survival in CVB3-positive dilated cardiomyopathy patients.
M
yocarditis is a potentially serious and sometimes fatal disease. In developed countries, it commonly results from a virus infection, often by coxsackievirus B3 (CVB3). 1, 2 The disease can have long-term sequelae, including dilated cardiomyopathy in which progressive dilatation and dysfunction of heart chambers and tissue fibrosis lead to chronic heart failure. 3, 4 Inflammatory cardiomyopathy is both a histological and a functional diagnosis characterized by myocarditis in association with systolic cardiac dysfunction in dilated cardiomyopathy. Genetically predisposed individuals who fail to eliminate viral genomes in infected hearts 4 are at risk for long-term inflammatory cardiomyopathy. Viral infection of the myocardium induces adverse autoimmunity directed against cardiac proteins. 5 The innate immune system plays a key role in constraining the viral spread in viral infection. Consistent with several studies performed in the mouse model of CVB3-induced inflammatory cardiomyopathy, type I interferons (IFNs) are obvious candidates for this innate immune response. Type I IFNs contribute to the suppression of viral titers and thereby ameliorate invasion of immune cells into the heart, contributing to improved survival in CVB3 infection. [6] [7] [8] Type I IFN-dependent processes resulted in improved cardiac function during viral cardiomyopathy 7, 9 and ensured long-term survival in CVB3-positive dilated cardiomyopathy patients. 10 Binding of type I IFNs to their cognate receptors results in the induction of IFN-stimulated gene of 15 kDa (ISG15), a small ubiquitin family protein consisting of 2 ubiquitinlike folds.
11 ISG15 is involved in the struggle against pathogens. [12] [13] [14] [15] [16] ISG15 modification, the process by which ISG15 is covalently attached to lysine residues of target proteins, is mediated through the sequential action of a type I IFN-induced E1-E2-E3 enzymatic cascade, 17 involving the E1-activating enzyme Ube1L, 18 E2-conjugating enzyme Ube2L6, 19 and E3 ligases Herc5 and Herc6 20 in humans and mice, respectively. The isopeptidase USP18 specifically removes ISG15 from ISG15-modified substrates. 21 Pursuing the aim to define host determinants that influence the pathogenesis of viral cardiomyopathy, we provide the first evidence for the impact of the intrinsic innate immune factor ISG15 in the myocardium. We found that ISG15 in cardiomyocytes contributed significantly to the suppression of viral replication and infectious virus yield in the heart. The absence of protein modification with ISG15 was accompanied by a profound exacerbation of myocarditis and by a significant increase in mortality and heart failure.
Methods

Mice and Virus Used
The CVB3 (cardiotropic Nancy strain) used in this study was prepared as previously described. 22 Five-to 6-week-old mice (female and male at a ratio 1:1) were infected intraperitoneally with 1×10 5 plaque-forming units of CVB3 (USP18 C61A/C61A and respective wild-type [WT] control: 2×10 5 plaque-forming units of CVB3). C57BL6/J mice were obtained from a stock breeding initially purchased from Jackson Laboratory. ISG15 −/− mice, 23 Ube1L −/− mice, 24 and USP18 C61A/C61A transgenic mice were originally generated as described elsewhere. This study conforms to the Berlin State guidelines for animal welfare. The protocol was approved by the Committee on the Ethics of Animal Experiments of Berlin State authorities.
Endomyocardial Biopsies
Patients with clinical symptoms and signs of heart failure (New York Heart Association class II-III) underwent right ventricular endomyocardial biopsies after exclusion of coronary artery disease and valvular cardiomyopathy. Histological evidence for myocarditis is based on the Dallas criteria and immunohistochemistry. Inflammation in endomyocardial biopsies was considered positive if immunohistochemical detection revealed focal or diffuse mononuclear infiltrates of ≥14 CD3 + T lymphocytes or Mac1 + macrophages per 1 mm 2 , in addition to enhanced expression of HLA class II molecules. 5 Control patients had the following: left ventricular ejection fraction >60%, left ventricular end-diastolic diameter <55 mm, and no inflammation. Patients with inflammatory cardiomyopathy had a left ventricular ejection fraction <60%, left ventricular end-diastolic diameter >55 mm, and inflammation. Patients with dilated cardiomyopathy had left ventricular ejection fraction <60%, left ventricular end-diastolic diameter >55 mm, and no inflammation. The study protocol was set up in accordance with the ethics principles in the Declaration of Helsinki and was approved by the local ethics committee. Written informed consent was obtained from all patients.
Cell Culture and Plasmids
Primary mouse cardiomyocytes were isolated from embryonic mouse hearts. 25 Human cardiac myocytes were purchased from ScienCell and cultured as described elsewhere. 26 ISG15 was induced by IFN-β (100 U/mL) or by polyinosinic:polycytidylic acid (poly[I:C]) (50 μg/mL). For ISG15 modification assays, cDNA copies of HA-ISG15, Ube1L, UBE2L6, and Herc5 were transfected. For ISG15 rescue experiments, primary cardiomyocytes were transduced with AdV-pzS2 ISG15 at a multiplicity of infection of 25 for 48 hours. 27 AdV-pzS2 lacking cDNA inserts served as control. For immune cell-based assays, splenocytes were obtained as described. 28 For natural killer (NK) cell assays, the NK cell containing cell fraction was enriched by Ficoll density gradient centrifugation (Biocoll, Biochrom) and magnetic cell separation (MACS, Miltenyi).
Statistics
Results of continuous variables are expressed as mean±SEM. For 2-group comparisons, unpaired t tests were used. In cases of detection of unequal variances (F test), an unpaired t test with the Welch correction was applied. For multiple-group comparisons, unequal-variance versions of ANOVA (1-way or 2-way ANOVA) were performed, followed by a Tukey-Kramer multiple-comparison procedure. Survival curves were estimated from the Kaplan-Meier procedure with the log-rank (Mantel-Cox) test to compare survival among groups. The Fisher exact test was applied for analyzing differences between categorical data. The significance threshold was set at the 0.05 level. GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA; www.graphpad.com) was used for data analysis
Results
CVB3-Induced Pathology Is Exacerbated in the Absence of ISG15
Differences in the genetic backgrounds in humans are mimicked by different inbred mouse strains. Transcriptomic profiling studies revealed an impaired induction of the ISG15 system in the A.BY/SnJ strain, which is susceptible to postviral inflammatory cardiomyopathy ( Figure I in the online-only Data Supplement). The precise role of ISG15 was analyzed during CVB3 myocarditis in ISG15 −/− mice. At postinfection day 8, both unconjugated ISG15 and ISG15-modified protein substrates were upregulated in the hearts of WT controls ( Figure 1A ). Small areas of myocardial inflammation were detected in WT littermates, whereas ISG15 −/− mice developed large foci with cardiomyocyte death and infiltration of inflammatory cells ( Figure 1B ). Myocarditis scores ( Figure 1C ) and the areas of inflammation were increased in ISG15 −/− mice ( Figure 1D ). Mac-3 + macrophages were identified to be the most abundant invading cell type ( Figure 1F ). Immunohistology for CD3 + T lymphocytes revealed an equal abundance of CD3 + T lymphocytes in both ISG15 −/− mice and WT littermates ( Figure 1E ). In line with marked invasion of inflammatory cells to the site of myocardial infection, left ventricular function was deteriorated at postinfection day 8 in ISG15
−/− mice, as reflected by impaired cardiac contractility (dP/dtmax) and relaxation (dP/dtmin), and decreased left ventricular end-systolic pressure compared with WT littermates (Table 1) .
The invasion of immune cells is mediated by proinflammatory cytokines and chemokines. Cardiac mRNA expression profiling of proinflammatory cytokines (tumor necrosis factor-α, interleukin-6, and interleukin-1β), and chemokines (monocyte-attracting CCL3, CXCL10, and T cell/dendritic by guest on April 20, 2017 http://circ.ahajournals.org/ Downloaded from cell-attracting CXCL2) revealed increased expression levels for all these immune cell-attracting mediators in ISG15 −/− mice during acute virus infection ( Figure 1G ).
ISG15 Acts via Modification of Target Proteins With ISG15
To discriminate whether the effects of ISG15 were attributed to unconjugated ISG15 or relied on ISG15 modification of target proteins, mice deficient in the ISG15 E1-activating enzyme Ube1L were investigated during CVB3 myocarditis. Unconjugated ISG15 was strongly induced in cardiac tissues during CVB3 myocarditis at postinfection day 8 ( Figure 2A ). The cardiac phenotype in Ube1L −/− mice during acute myocarditis resembled that observed in ISG15 −/− mice ( Figure 2B-2D ). Increased myocarditis scores ( Figure 2C ) in Ube1L −/− mice demonstrated that the disease-attenuating effect of ISG15 during CVB3 myocarditis was attributed to ISG15 modification of target proteins. To evaluate whether increased ISG15-modification could be beneficial during CVB3 myocarditis, mice with inactivated catalytic activity of the ISG15-specific isopeptidase USP18 were studied on CVB3 infection. USP18
C61A/C61A knock-in mice carry a mutation within the active site of the ISG15 deconjugating enzyme USP18 (described elsewhere). In cardiomyocytes obtained from these mice, we observed increased levels of ISG15-modified proteins on stimulation with the TLR3 agonist polyinosinic:polycytidylic acid (poly[I:C]) ( Figure 2E ). In CVB3-infected mice, we found increased levels of ISG15 conjugates in cardiac homogenates obtained from USP18 C61A/ C61A mice at postinfection day 8 ( Figure 2E ). This stabilization of ISG15-conjugated proteins in USP18 C61A/C61A mice coincided with the detection of smaller myocarditis foci during CVB3 myocarditis ( Figure 2F and 2G).
ISG15 Protects Against CVB3-Induced Heart Failure and Long-Term Inflammation
In agreement with impaired contractility at postinfection day 8 in CVB3-infected ISG15
−/− mice, we observed increased lung −/− mice depict complete deficiency in ISG15 modification of putative target proteins (representative for n=6 mice). B, Representative cardiac hematoxylin and eosin stainings are shown. C, To quantify myocardial damage, the myocarditis score was determined as outlined above. D, Area of inflammation (AoI) in heart tissue sections (mm 2 ) was monitored. E through G, USP18
C61A/ C61A transgenic mice are devoid of the isopeptidase activity of USP18. E, Left, ISG15 modification was induced with poly(I:C) acid (50 μg/mL) for 24 hours in primary cardiomyocytes that were obtained from USP18 C61A/C61A mice and wild-type (WT) controls. Right, USP18 C61A/C61A mice and WT controls were infected with CVB3 and euthanized at postinfection day 8. Cardiac homogenates from CVB3-infected USP18 C61A/C61A mice show increased amounts of ISG15-modified proteins compared with WT controls (*unspecific background of the antibody; 3 individual mice per strain are shown). F, Representative hematoxylin and eosin stainings of cardiac sections from USP18
C61A/C61A mice and WT controls (n=10 mice). G, Myocarditis scores in hematoxylin and eosin-stained tissue sections were determined. (Table 1) . Taken together, these findings show that induction of the ISG15 machinery during acute viral myocarditis ameliorated chronic disease progression.
Ablation of ISG15 Results in Loss of Viral Control in the Heart
The extent of cardiac inflammatory lesions correlates spatially and temporally with viral replication during acute viral myocarditis. CVB3-specific in situ hybridization analysis on cardiac tissue sections revealed increased CVB3-positive signals in both ISG15 −/− and UbelL −/− mice compared with WT controls ( Figure 4A ). ISG15 substantially contributed to suppression of viral copy numbers and infectious virus yield, and this process involved protein modification with ISG15 ( Figure 4A ). Another important observation was the persistence of CVB3 genomes in ISG15 −/− mice at postinfection day 28, whereas CVB3 was not detected in any of the WT controls ( Figure 4B ). To provide evidence supporting the hypothesis that ISG15 represents an innate mechanism to fight viral infection in cardiomyocytes, viral replication was studied in primary embryonic cardiomyocytes. To discriminate ISG15-negative cells from ISG15-positive cardiomyocytes, ISG15 expression in ISG15 −/− cardiomyocytes was restored via adenoviral gene transfer of ISG15. CVB3 infection of ISG15-positive cardiomyocytes resulted in drastically reduced viral copy numbers and viral titers compared with ISG15-negative cardiomyocytes ( Figure 4E ).
ISG15 Modification Is Not Involved in the Activation of NK Cells and T Cells
Immune surveillance in CVB3 myocarditis includes NK cells and T cells, both of which contribute to viral clearance in hearts. 1 It was demonstrated only recently that ISG15 is involved in the activation of NK and T cells. 12 Therefore, we addressed the function of ISG15 on NK-and T-cell immunity in CVB3 infection. NK cell function relies on activating and inhibitory receptors. Two of these receptors, the NK cell-activating receptor NKG2D and the inhibitory receptor killer lectin-receptor gene 1 (KLRG1), were monitored during acute CVB3 infection, and no effect of ISG15 was observed ( Figure 5A CVB3-infected mice compared with uninfected controls. NK cell-dependent cytotoxicity was independent of ISG15 ( Figure 5B ). NK cells are also the primary and very potent producers of IFN-γ. The increase in IFN-γ production by NK cells on CVB3 infection was found to be significantly impaired in ISG15 −/− mice. With the induction of unconjugated ISG15 in Ube1L −/− mice on CVB3 infection, IFN-γ production by NK and T cells was efficiently induced, and no differences compared with WT controls were detected ( Figure 5C ). Among other functions, IFN-γ shapes the differentiation of naive CD4 + T cells into T helper 1 effectors and stimulates CD8 + T-cell activation to control viral infection. Despite the fact that after ex vivo T-cell stimulation the IFN-γ production by ISG15 −/− CD8 + and CD4 + T cells was impaired ( Figure 5D ), the absence of ISG15 did not affect the CD69 activation marker expression on T cells or the amount of antigen-experienced (CD137) CD4 + and CD8 + T cells ( Figure 5E ). Moreover, ISG15 had no impact on CD4 + T-cell differentiation (regulatory T-cell levels are shown in Figure 5F ) or on antiviral humoral immunity determined by the amount of CVB3-specific IgG ( Figure 5G ).
ISG15 Interferes With CVB3 2A Protease Activity
Previously, it was reported that the ISG15 system is designed to target newly synthesized proteins. Therefore, viral proteins in particular represent principal targets of the ISG15 conjugation apparatus in CVB3-infected cardiomyocytes. 30 Here, we focused on the role of ISG15 to modulate CVB3-protease 2A (2APro), a viral protease that interferes with host cell translation. 2APro-dependent cleavage of the mammalian eukaryotic translation initiation factor 4G (eIF4G) results in shutoff of host cell protein translation. 31 First, we addressed the question of whether 2APro is a substrate for ISG15 conjugation. Immunoprecipitation and Ni-NTA pull-downs of His-tagged 2APro obtained from in vitro ISG15 conjugation assays demonstrated 2APro to be partially modified by ISG15 ( Figure 6A and 6B) . In addition, a 2APro K→R mutant was generated by site-directed mutagenesis whereby lysine residues that are needed for covalent ISG15 binding had been mutated to arginine. Hisimmunoprecipitation of this construct in ISG15 conjugation assays confirmed that 2APro is a target for ISG15 conjugation ( Figure 6B, right) . Next, the question of whether ISG15 alters CVB3 2APro-dependent cleavage of eIF4G was addressed. HeLa cells as an established cell culture model of CVB3 infection were studied.
32 ISG15 knockdown by siRNA increased the cleavage of eIF4G that was induced both by 2APro overexpression and on CVB3 infection ( Figure 6C) . Induction of the ISG15 machinery in HeLa cells reduced 2APro-dependent cleavage of eIF4G ( Figure 6D ). Further evidence for the key role of ISG15 modification in limiting proteolysis by CVB3 2APro was provided with 2APro K→R mutants. The failure to modify 2APro with ISG15 facilitated eIF4G cleavage in these mutants ( Figure 6E ).
We then investigated whether ISG15 as demonstrated in HeLa cells affects 2APro-dependent cleavage of eIF4G also in cardiomyocytes. eIF4G cleavage was reduced on induction of endogenous ISG15 in CVB3-infected primary embryonic cardiomyocytes ( Figure 6F ). In an alternative approach, ISG15 expression was restored in cardiomyocytes obtained from ISG15 −/− mice by adenoviral gene transfer of ISG15 (AdV5-ISG15). Induction of the ISG15 apparatus resulted in reduced eIF4G cleavage in both CVB3-infected cardiomyocytes and 2APro-transfected cardiomyocytes ( Figure 6G and 6H). Taken together, these data demonstrate that ISG15 modification of 2APro hinders the cleavage of eIF4G during CVB3 infection.
ISG15 Controls Viral Titers in Human Cardiac Myocytes
Next, we addressed the question of whether ISG15 may also affect viral replication in human cardiac myocytes. The ISG15 apparatus was induced in human cardiac myocytes by adenoviral gene transfer of ISG15 (Figure 7A and 7B) . Infectious virus yield was reduced in ISG15-expressing cardiomyocytes compared with controls ( Figure 7C ). This first demonstration of suppressed viral titers in ISG15-overexpressing primary human cells provoked us to study the ISG15 system in patients with viral cardiomyopathy. As depicted in Figure 7D and 7E, ISG15 was upregulated at both the mRNA and protein levels in patients with acute myocarditis and inflammatory cardiomyopathy.
Discussion
In this report, we demonstrated that the ISG15 conjugation system is a key intrinsic innate immune pathway in cardiomyocytes to fight the battle against invading viral pathogens. By suppressing viral titers in cardiomyocytes, ISG15 improves survival, protects against congestive heart failure, and prevents ongoing inflammation (Figure 8 ). Gene-targeting technologies were used to study the in vivo function of the ISG15 system in germline ISG15 −/− and the Ube1L −/− mice. One potential limitation of this tool is the risk that phenotypes attributed primarily to the germline knocked out gene of interest could be attributed to tightly linked loci immediately flanking the ablated gene or unlinked loci located throughout the genetic background of the knockout strain. 33 Application of 2 different germline knockout mouse models, namely Immunocomplexes were analyzed by SDS-PAGE and subjected to immunoblotting with antibody to V5 and ISG15 (smear pattern; *distinct bands are unspecific background signals). Right, 2APro K→R mutant was generated by site-directed mutagenesis. ISG15 modification assays were performed as described. His-immunoprecipitations yielded ISG15-modified 2APro in the wild-type (WT) construct only. C, Depletion of ISG15 in HeLa cells by siRNA (on-target) vs off-target control. HeLa cells were then either transfected with CVB3 2APro (anti-V5 indicates 2APro expression) or infected with CVB3 (multiplicity of infection of 0.1). Eukaryotic translation initiation factor 4G (eIF4G) cleavage was monitored by immunoblotting. D, HeLa cells were transfected with ISG15, Ube1L, Ube2L6, and Herc5. pcDNA3.1 was the vector control. CVB3 2APro was transfected (n-control vector), and eIF4G cleavage was monitored. E, CVB3 2APro-K→R mutant lacks lysine residue that is required for covalent binding of ISG15. 2APro K→R mutant and 2APro WT were transfected in HeLa ISG15 conjugation systems, and eIF4G cleavage was monitored. Table 2 . ISG15 expression was determined in EMBs by quantitative polymerase chain reaction after a preamplification step. E, Immunohistochemical detection of ISG15 (blue staining) in EMBs obtained from patients with acute myocarditis, inflammatory cardiomyopathy, and dilated cardiomyopathy (slides shown are representative of n=8 patients).
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Amelioration of acute myocarditis / Inflammatory cardiomyopathy rescue of the ISG15 gene in primary cardiomyocytes that were obtained from ISG15 −/− mice. Once CVB3 interacts with the receptor on cardiomyocytes, the host immune system begins to counteract infection. A major initial response of mammalian cells to virus infection is the production of type I IFNs, which in turn induce the synthesis of a variety of antiviral effector systems. 34, 35 ISG15 is one of the most predominant among the several hundred proteins induced by IFN-α/β. Together with ISG15, the ISG15-conjugating enzymes Ube1L, Ube2L6, and Herc5 are upregulated in heart tissue early on CVB3 infection in C57BL/6 mice. In contrast, upregulation of the ISG15 system was impaired in mice that are susceptible to dilated cardiomyopathy. 36 With a recent report on mutations within the ISG15 gene in 2 families with mendelian susceptibility to mycobacterial disease, the function of unconjugated ISG15 as a cytokine that modulates cellular immunity has gained particular interest.
12 ISG15 regulates IFN-γ production by NK and T cells in CVB3 infection. However, the pathophysiological impact of ISG15-dependent IFN-γ immunity on viral titers is dispensable in CVB3 myocarditis. ISG15 is known to inhibit the replication of many, 13, 14, 16, 37 but not all, 15, 23 viruses. The suppression of CVB3 titers in cardiomyocytes by ISG15 substantially altered the phase of viral myocarditis that spans from the time of initial virus infection to elimination of viral genomes. Ablation of ISG15 promoted cardiomyocytes death, leading to cardiac dysfunction, decompensation to heart failure, and death. Infection of cardiomyocytes by CVB3 results in a precipitous decline in host cell protein synthesis, whereas translation of CVB3 RNA is favored. The repression of host cell translation is generally preceded by CVB3 2APro-dependent cleavage of eIF4G, 38,39 the latter being a component of the capbinding protein complex eIF4F. CVB3 genomic RNA lacks the cap structure, and cap-independent translation of CVB3 occurs. 40 The inhibition of CVB3 replication by ISG15 can be partially attributed to reduced cleavage of eIF4G by the viral protease 2APro. Therefore, ISG15 may counterbalance the decline in host cell protein translation in infected cardiomyocytes. In addition to CVB3 2APro, other host cell targets may become substrates of ISG15 and thus contribute to preserving eIF4G function in CVB3 infection. Type I IFN-dependent ISG15 modification in remote areas of infection could precondition cardiomyocytes to make them less susceptible to CVB3-infection. Thus, ISG15 could contribute to the focal disease pattern in viral myocarditis.
ISG15 is known to interfere with various cellular pathways such as protein translation and signal transduction and thus regulates cytokines and chemokines such as CXCL-10. 41, 42 ISG15 counterbalanced the pathogenic cytokine response also in vivo in CVB3 myocarditis. This is particularly important because inflammation is related to poor outcome in patients with suspected myocarditis and persistent cardiac dysfunction. 43 However, the molecular mechanisms of ISG15 action on the cytokine burden are not yet well defined. In Chikungunya virus, influenza virus B, and vaccinia virus infection, ISG15 deficiency contributed to elevated levels of proinflammatory cytokines, 13, 15, 37 the latter being in agreement with the increased cytokine responses in ISG15 −/− mice during CVB3 myocarditis described here. Because cytokine expression was increased in CVB3-infected Ube1L −/− mice also (data not shown), ISG15-dependent diminution of pathological cytokine levels in CVB3 myocarditis involved the process of ISGylation. Increased levels of tumor necrosis factor-α and interleukin-1β promote local tissue destruction and increase vascular permeability. Together with the chemokines CCL2, CXCL2, and CCL3, this cytokine milieu attracts both sensitized T cells and monocytes/macrophages. Therefore, detrimental effects even in remote uninfected areas of the myocardium occur, 44 contributing to injury and remodeling of the heart, as observed in both CVB3-infected ISG15 −/− and Ube1L −/− mice. An adverse inflammatory response was identified to be a requisite to progression to inflammatory cardiomyopathy in patients with viral myocarditis. 43 Transition to sustained myocardial inflammation by persistence of viral genomes as observed in ISG15 −/− mice propagates chronic inflammation and eventually leads to myocardial fibrosis in inflammatory cardiomyopathy. ISG15 suppressed infectious virus yield also in human cardiac myocytes. Therefore, defects within the ISG15 conjugation apparatus might also affect disease progression in patients with viral myocarditis.
The activation of innate immunity in CVB3 infection reflects a critical time point that determines the clinical outcome. If [45] [46] [47] ISG15 modification at the critical stage of acute viral replication suppresses viral replication and ensures effective elimination of CVB3 from the heart (Figure 8 ).
Conclusions
The ISG15 conjugation system represents a critical innate response mechanism in cardiomyocytes to fight the battle against invading pathogens that initiate the fatal pathway to chronic viral cardiomyopathy. Further research is needed to evaluate the therapeutic potential to interfere with the ISG15 apparatus in viral heart disease. Representative HE-stainings and myocarditis scores are shown.
